Huaier Granule for Prevention of Recurrence and Metastasis of Stage II and III Non-small Cell Lung Cancer (NSCLC)
This study including two parts，one part is a randomized clinical trial design，another part is a registration study.
Non-small Cell Lung Cancer
DRUG: Huaier Granule|OTHER: placebo
disease-free survival, disease-free survival, 2-year
overall survivals, overall survivals, 2-year|Quality of Life, Quality of Life-EORTC QLQ-C30, 2-year|KPS, Karnofsky, 2-year|ECOG-PS, ECOG-PS, 2-year|CEA, tumor markers, 2-year|CYFRA21-1, tumor markers, 2-year|SCC, tumor markers, 2-year
This study include a multicenter, randomized, controlled, double-blind, placebo-controlled post-market clinical trial and a registration study.

The randomized clinical trial included subjects (n =798) will be randomly divided into experimental (n = 532) and control groups (n =266) according to a random number table. Patients in the experimental group will receive Huaier Granule (20g/time, 3 times/d). Patients in the control group will receive placebo (20g/time, 3 times/d). The registration study plan to recruitment at least 300 patients.

The primary outcome measures is disease-free survival，secondary outcome measures is 2-year overall survivals, ECOG-performance status, Karnofsky performance score and tumor markers (CEA、CYFRA21-1、SCC).